23,755 Shares in Immunocore Holdings plc (NASDAQ:IMCR) Purchased by Verition Fund Management LLC

Verition Fund Management LLC purchased a new position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 23,755 shares of the company's stock, valued at approximately $739,000.

Other large investors have also recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. boosted its stake in Immunocore by 6.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 22,622 shares of the company's stock worth $767,000 after purchasing an additional 1,390 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Immunocore by 16.2% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company's stock valued at $13,470,000 after acquiring an additional 55,463 shares in the last quarter. Fiera Capital Corp lifted its stake in Immunocore by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 875,593 shares of the company's stock worth $29,674,000 after purchasing an additional 9,181 shares in the last quarter. TD Asset Management Inc lifted its stake in Immunocore by 23.2% in the 2nd quarter. TD Asset Management Inc now owns 264,896 shares of the company's stock worth $8,977,000 after purchasing an additional 49,882 shares in the last quarter. Finally, Candriam S.C.A. boosted its holdings in Immunocore by 65.8% in the 2nd quarter. Candriam S.C.A. now owns 313,423 shares of the company's stock valued at $10,621,000 after purchasing an additional 124,417 shares during the period. 84.50% of the stock is owned by institutional investors.

Immunocore Price Performance

Immunocore stock remained flat at $31.85 during mid-day trading on Tuesday. 86,094 shares of the company's stock traded hands, compared to its average volume of 499,600. The business has a 50 day moving average of $32.32 and a 200 day moving average of $35.65. Immunocore Holdings plc has a 1-year low of $29.72 and a 1-year high of $76.98. The stock has a market cap of $1.59 billion, a PE ratio of -33.53 and a beta of 0.73. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company had revenue of $80.25 million during the quarter, compared to analysts' expectations of $78.94 million. During the same period in the prior year, the business posted ($0.59) EPS. Immunocore's quarterly revenue was up 23.7% compared to the same quarter last year. On average, equities research analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on IMCR shares. Cantor Fitzgerald restated an "overweight" rating on shares of Immunocore in a research note on Monday, September 9th. Morgan Stanley decreased their price objective on shares of Immunocore from $80.00 to $74.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of Immunocore in a research report on Thursday, October 24th. Guggenheim lowered shares of Immunocore from a "buy" rating to a "neutral" rating in a report on Monday, October 7th. Finally, Mizuho cut shares of Immunocore from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $72.00 to $38.00 in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, Immunocore currently has an average rating of "Moderate Buy" and an average price target of $69.18.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.